MYPINPAD
14.7.2020 01:03:13 CEST | Business Wire | Press release
MYPINPAD , the global leader in secure personal authentication solutions is the first company in the world to achieve Payment Card Industry (PCI) Security Standards Council (SSC) certification for its Android software-based Contactless Payments on Commercial off-the-shelf (CPoC) solution, enabling contactless payments on smart devices. As the first solution globally certified to accept contactless payments on these devices without requiring additional hardware, this significant step accelerates unparalleled possibilities in customer experience innovation for merchants and other businesses in the payments chain.
Accreditation for MYPINPAD’s contactless payment solution follows the company’s recent PCI SSC SPoC certification for its software only PIN Entry solution for iOS and Android (PIN on mobile), also a global first. The combined capability of tap and PIN on smart mobile devices means a 100 percent software-based payments future. It enables all merchants globally to democratise payments with integrated, scalable digital customer experiences, replacing traditional POS terminals with smart mobile devices.
This announcement is fantastic news for face to face retailers and service providers, creating access to a lower cost, highly secure PCI certified contactless solution. This is especially timely with contactless limits around the world being raised in response to COVID-19, which has seen cash usage reduced by half. With long-term effects of the pandemic uncertain, MYPINPAD is taking steps to help future proof retailers by creating a face-to-face payment system that is more flexible, safer, and available to businesses of all sizes.
MYPINPAD’s goal is to help drive mobile device acceptance exponentially from 100 million currently to over 400 million by 2024.
CEO of MYPINPAD, Colin Greene, commented: “With each new accreditation we get closer to the true democratisation of payment acceptance. This ultimately means more secure digital payment experiences for merchants and consumers worldwide. That’s why we are delighted to be the first company in the world to have achieved PCI certification for our contactless solution, especially after our recent announcement of being the first to achieve PCI accreditation for our PIN-entry software only solution on IOS and Android. By increasing access to lower cost, highly secure and innovative globally certified payment solutions for the industry and our partners, we promote both growth and financial inclusion.”
Blake Rosenthal, Executive Vice President of Acceptance Solutions at Mastercard , adds; “Consumers and merchants are looking for fast, safe, and secure checkout experiences,” “MYPINPAD’s PCI accreditation is a key milestone to the growth, diversification, and scale of contactless payment solutions, increasing speed at checkout and reducing operational costs by eliminating all hardware accessories.”
MYPINPAD’s solution is easily integrated into third party applications and delivered ‘As-a-Service’. It reduces cost across the entire face-to-face payment ecosystem by meeting PCI security standards through software updates alone. This relieves pain-points like the cost of traditional payment and POS hardware for smaller retailers, while serving larger retailers by significantly reducing maintenance, replacement costs of aging hardware-centric POS systems and improving CX with trusted and familiar devices.
Visit www.mypinpad.com to discover more about this transformational technology.
***ENDS***
About:
MYPINPAD is the global leader in secure personal authentication solutions residing on commercially available smartphones and tablets. MYPINPAD’s proprietary and globally patented technology removes the reliance on specialised hardware for personal authentication.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200713005610/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
